Navigation Links
63 percent of RA patients suffer psychiatric disorders, with depressive spectrum conditions most likely

Copenhagen, Denmark, Friday 12 June 2009: Over half (63%) of patients with rheumatoid arthritis (RA) also suffer from psychiatric disorders, with the majority of these (87%) occurring in the depressive spectrum, according to the results of a new study presented today at EULAR 2009, the Annual Congress of the European League Against Rheumatism in Copenhagen, Denmark. Interestingly, over half (52%) of the patients studied indicated that they had experienced stress events before the onset of their RA.

The study also revealed a number of other interesting findings about the emotional burden of RA:

  • Cognitive dysfunction was diagnosed in 23% of patients, with 16% of this attributed to depression
  • A third (33%) suffered from sleep disorders
  • Those with depression also exhibited more severe RA (measured by X-ray), greater functional insufficiency and pain, as well as having received less aggressive treatment than patients without depression. (No significant differences in age, duration of illness, gender or DAS28* scores were noted between the two groups)
  • Significantly, cognitive impairments were found more often (p=0.02) in patients older than 50 years (39% vs. 9%)
  • The age of the first prednisone intake was significantly higher (p<0.05) in patients with depression compared to those without (48 vs. 30 years)

Dr Tatiana Lisitsyna from the State Institute of Rheumatology RAMS, Russian Federation, who conducted the study, said: "Psychiatric disorders are a very common comorbidity for people with RA, and they tend to be stress-related and associated with disease activity and chronic pain. Evaluating and addressing the mental health of those with RA should be a regular feature of rheumatology practice to improve quality of life and reduce the potentially distressing psychological burden of RA."

In the study, the disease activity of 75 patients with American College of Rheumatology (ACR) defined RA (96% female, median age 52 years (46-55), median disease duration 12 years (4-22) was assessed using DAS28* with a median score of 4.98 (3.71 - 6.4). Median prednisone intake duration was 34 months (3-72) and 80% of patients were taking DMARDs (49% methotrexate; 23% leflunomide). Using the Brief Pain Inventory (BPI) scale to assess pain, 74% were considered to have either severe (7-10 points) or moderate (5-6 points) pain.

Psychiatric disorders were diagnosed in accordance with the ICD-10 (International Classification of Disease) scale, and other psychiatric and psychological scales used included: the Hospital Anxiety and Depression Scale for screening, the Hamilton Anxiety Rating Scale and the Montgomery-Asberg Depression Rating Scale. Projective psychological methods were employed for evaluation of cognitive function.

* DAS28 (Disease Activity Score) is an index used by physicians to measure how active an individual's RA is. It assesses number of tender and swollen joints (out of a total of 28), the erythrocyte sedimentation rate (ESR, a blood marker of inflammation), and the patient's 'global assessment of global health'. A higher score indicates more active disease.


Contact: Rory Berrie
European League Against Rheumatism

Related medicine news :

1. Allscripts Announces Convertibility of its Outstanding 3.50 Percent Senior Debentures
2. Over 60 percent of all US bankruptcies attributable to medical problems
3. Cardinal Health Increases Quarterly Dividend By 25 Percent
4. Niutang to Expand Sucralose Capacity 66 Percent by 2012
5. New Virginia Poll: 71 Percent of Voters Strongly Support FDA Regulation of Tobacco Products
6. National study finds youth baseball-related injuries down 25 percent
7. New Initiative Poised To Reduce Maternal Mortality Rates By More Than 25 Percent
8. MedPro Imaging Reports 118 Percent Growth For First Quarter
9. Consumer Reports Poll: Thirty-One Percent of Americans Never Use Sunscreen
10. Sales of Antiretroviral Agents Will Drive Substantial Six Percent Annual Growth in the HIV Drug Market Through 2013
11. GlaxoSmithKline Travel Health: 55 percent of travellers needlessly put themselves at risk from a potentially fatal virus
Post Your Comments:
(Date:10/13/2015)... ... October 13, 2015 , ... Purdue University announced Tuesday (Oct. ... Initiative aimed at enhancing Purdue’s life sciences research and graduate education. The initiative ... , The investment will result in cohesive efforts across several colleges and is ...
(Date:10/13/2015)... ... 13, 2015 , ... "My friend's son suffers from eczema, and he had ... an inventor from Platteville, Colo. "I came up with this kit as a way ... to prevent a child from rubbing or scratching his or her face. This protects ...
(Date:10/13/2015)... (PRWEB) , ... October 13, 2015 , ... ProText Kinetic ... X . With ProText Kinetic Panel, users can create energetic text animations in any ... preset into the Final Cut Pro X timeline and stylize the text. With intuitive ...
(Date:10/13/2015)... ... October 13, 2015 , ... Relay (, a technology ... today a significant contract that will provide its award-winning private messaging solution to ... the growing success of its Relay program, IBX Wire™, which now has over ...
(Date:10/13/2015)... ... October 13, 2015 , ... Leading Internet marketing product review ... "Publish Academy" training course . Singal's new program, in which he reveals his ... around the Internet are weighing in with reviews. , "Considering the fairly high ...
Breaking Medicine News(10 mins):
(Date:10/13/2015)... 2015  Nanomedical Diagnostics, a biotech company developing ... diagnostics, announces the completion of a Series A ... Ventures. --> ... monitoring and diagnostic platforms that empower individuals to ... will enable the company to commercially release AGILE ...
(Date:10/13/2015)... Oct. 9, 2015 Research and Markets ( ... "Kombucha Market by Types (Bacteria, Yeast, Mold, Others), Flavors ... Flowers, Others), & by Region - Forecasts to 2020" ... --> --> The global ... few years. In terms of value, the market is ...
(Date:10/13/2015)... Oct. 13, 2015   Micell Technologies , Inc. ... and II trials of its MiStent Sirolimus Eluting Absorbable ... ) were presented at the 27th Annual Transcatheter Cardiovascular ... San Francisco , October 11-15. TCT is the ... MiStent SES was designed to optimize vessel healing in ...
Breaking Medicine Technology: